ロード中...
Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia
BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184418/ https://ncbi.nlm.nih.gov/pubmed/19441109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24367 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|